J-B Bachet1,2, N Moreno-Lopez3, L Vigano4, U Marchese5, M Gelli6, L Raoux7, S Truant8, C Laurent9, A Herrero10, B Le Roy11, S Deguelte Lardiere12, G Passot13, V Hautefeuille14, C De La Fouchardiere15, P Artru16, T Ameto17, J Y Mabrut18, L Schwarz19, B Rousseau20, C Lepère21, R Coriat22, A Brouquet23,24, A Sa Cunha25,24, S Benoist23,24. 1. Sorbonne Université, University Pierre and Marie Curie, Paris, France. 2. Department of Hepato-Gastroenterology, Hôpital Pitié Salpêtrière, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France. 3. Department of Digestive Surgery, Dijon University Hospital, Dijon, France. 4. Division of Hepatobiliary and General Surgery, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. 5. Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France. 6. Department of General Surgical Oncology, Gustave Roussy Institute, Villejuif, France. 7. Department of Digestive Surgery, University Hospital of Toulouse, University Paul Sabatier, Toulouse, France. 8. Department of Digestive Surgery and Transplantation, Lille University Hospital, Lille, France. 9. Department of Hepatobiliopancreatic Surgery and Liver Transplantation, Saint André Hospital, Bordeaux, France. 10. Department of General Surgery, Division of Transplantation, University of Montpellier - College of Medicine, Saint Eloi Hospital, Montpellier, France. 11. Department of Digestive Surgery, Estaing University Hospital, Clermont-Ferrand, France. 12. Department of Hepato-Gastroenterology and Digestive Oncology, Robert-Debré University Hospital, Reims, France. 13. Department of Surgical Oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France. 14. Department of Gastroenterology, Amiens-Picardie University Hospital, Amiens, France. 15. Department of Oncology, Centre Léon Bérard, Lyon, France. 16. Department of Oncology, Hôpital Privé Jean Mermoz, Lyon, France. 17. Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France. 18. Department of Hepatobiliopancreatic Surgery and Liver Transplantation, Hôpital Croix Rousse, Lyon, France. 19. Department of Digestive Surgery, Hôpital Charles Nicolle, Rouen, France. 20. Department of Oncology, Henri Mondor Hospital, AP-HP, Créteil, France. 21. Department of Gastroenterology and Digestive Oncology, European Georges Pompidou Hospital, AP-HP, Paris, France. 22. Department of Gastroenterology and Digestive Oncology, Cochin Hospital, AP-HP, Paris, France. 23. Department of Digestive Surgery and Surgical Oncology, Bicêtre Hospital, AP-HP, Paris-Sud University, Le Kremlin Bicêtre, France. 24. Paris-Sud University, Le Kremlin Bicêtre, France. 25. Department of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, Paul Brousse Hospital, Villejuif, France.
Abstract
BACKGROUND: BRAF mutation is associated with a poor prognosis in patients with metastatic colorectal cancer. For patients with resectable colorectal liver metastases (CRLMs), the prognostic impact of BRAF mutation is unknown and the benefit of surgery debated. This nationwide intergroup (ACHBT, FRENCH, AGEO) study aimed to evaluate the oncological outcome of patients undergoing liver resection for BRAF-mutated CRLMs. METHODS: The study included patients who underwent resection for BRAF-mutated CRLMs in 24 centres between 2012 and 2016. A case-matched comparison was made with 183 patients who underwent resection of CRLMs with wild-type BRAF during the same interval. RESULTS: Sixty-six patients who underwent resection for BRAF-mutated CRLMs in 24 centres were compared with 183 patients with wild-type BRAF. The 1- and 3-year disease-free survival (DFS) rates were 46 and 19 per cent for the BRAF-mutated group, and 55·4 and 27·8 per cent for the group with wild-type BRAF (P = 0·430). In multivariable analysis, BRAF mutation was not associated with worse DFS (hazard ratio 1·16, 95 per cent c.i. 0·72 to 1·85; P = 0·547). The 1- and 3-year overall survival rates after surgery were 94 and 54 per cent respectively among patients with BRAF mutation, and 95·8 and 82·9 per cent in those with wild-type BRAF (P = 0·004). Median survival after disease progression was 23·0 (95 per cent c.i. 11·0 to 35·0) months among patients with mutated BRAF and 44·3 (35·9 to 52·6) months in those with wild-type BRAF (P = 0·050). Multisite disease progression was more common in the BRAF-mutated group (48 versus 29·8 per cent; P = 0·034). CONCLUSION: These results support surgical treatment for resectable BRAF-mutated CRLM, as BRAF mutation by itself does not increase the risk of relapse after resection. BRAF mutation is associated with worse survival in patients whose disease relapses after resection of CRLM, as for non-metastatic colorectal cancer.
BACKGROUND:BRAF mutation is associated with a poor prognosis in patients with metastatic colorectal cancer. For patients with resectable colorectal liver metastases (CRLMs), the prognostic impact of BRAF mutation is unknown and the benefit of surgery debated. This nationwide intergroup (ACHBT, FRENCH, AGEO) study aimed to evaluate the oncological outcome of patients undergoing liver resection for BRAF-mutated CRLMs. METHODS: The study included patients who underwent resection for BRAF-mutated CRLMs in 24 centres between 2012 and 2016. A case-matched comparison was made with 183 patients who underwent resection of CRLMs with wild-type BRAF during the same interval. RESULTS: Sixty-six patients who underwent resection for BRAF-mutated CRLMs in 24 centres were compared with 183 patients with wild-type BRAF. The 1- and 3-year disease-free survival (DFS) rates were 46 and 19 per cent for the BRAF-mutated group, and 55·4 and 27·8 per cent for the group with wild-type BRAF (P = 0·430). In multivariable analysis, BRAF mutation was not associated with worse DFS (hazard ratio 1·16, 95 per cent c.i. 0·72 to 1·85; P = 0·547). The 1- and 3-year overall survival rates after surgery were 94 and 54 per cent respectively among patients with BRAF mutation, and 95·8 and 82·9 per cent in those with wild-type BRAF (P = 0·004). Median survival after disease progression was 23·0 (95 per cent c.i. 11·0 to 35·0) months among patients with mutated BRAF and 44·3 (35·9 to 52·6) months in those with wild-type BRAF (P = 0·050). Multisite disease progression was more common in the BRAF-mutated group (48 versus 29·8 per cent; P = 0·034). CONCLUSION: These results support surgical treatment for resectable BRAF-mutated CRLM, as BRAF mutation by itself does not increase the risk of relapse after resection. BRAF mutation is associated with worse survival in patients whose disease relapses after resection of CRLM, as for non-metastatic colorectal cancer.
Authors: S G Larsen; M A Goscinski; S Dueland; S E Steigen; E Hofsli; A Torgunrud; M Lund-Iversen; V J Dagenborg; K Flatmark; H Sorbye Journal: Br J Cancer Date: 2021-12-09 Impact factor: 7.640
Authors: Jack Martin; Angelica Petrillo; Elizabeth C Smyth; Nadeem Shaida; Samir Khwaja; H K Cheow; Adam Duckworth; Paula Heister; Raaj Praseedom; Asif Jah; Anita Balakrishnan; Simon Harper; Siong Liau; Vasilis Kosmoliaptsis; Emmanuel Huguet Journal: World J Clin Oncol Date: 2020-10-24
Authors: Francesco Fiz; Guido Costa; Nicolò Gennaro; Ludovico la Bella; Alexandra Boichuk; Martina Sollini; Letterio S Politi; Luca Balzarini; Guido Torzilli; Arturo Chiti; Luca Viganò Journal: Diagnostics (Basel) Date: 2021-06-25